Clinical Trial Update: Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II study investigating afatinib plus bevacizumab for metastatic non-small cell lung cancer with EGFR G719X, S768I, and L861Q mutations; current status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: PFS | Phase 2 | Status: UNKNOWN